Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00454740
Status:
COMPLETED
Last Update Posted:
2014-09-18
First Post:
2007-03-29
Brief Title:
Efficacy Safety Study of VESIcare Solifenacin Succinate in Patients Wishing to Switch From Detrol LA for Treatment of Overactive Bladder
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
An Open-Label Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5 and 10mg VESIcare Solifenacin Succinate in Patients Who Wish to Switch From Detrol LA Tolterodine Tartrate Extended Release for the Treatment of Overactive Bladder Symptoms Versus VESIcare Efficacy and Research Study US
Status:
COMPLETED
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VERSUS
Brief Summary:
To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome urgency with or without urge incontinence usually with frequency and nocturia and wish to switch from tolterodine tartrate extended release to solifenacin succinate due to lack of sufficient improvement in urgency episodes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None